Welcome to our dedicated page for Schrodinger SEC filings (Ticker: SDGR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Schrödinger, Inc. (SDGR) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, alongside AI-powered tools that help interpret key documents. As a Nasdaq-listed issuer, Schrödinger files current reports on Form 8-K, annual reports on Form 10-K and quarterly reports on Form 10-Q, among other documents, to provide transparency into its operations, governance and financial condition.
Recent Form 8-K filings illustrate the range of topics covered in SDGR’s regulatory reporting. The company has furnished press releases announcing quarterly financial results under Item 2.02, giving detail on software revenue, drug discovery revenue, software gross margin, operating expenses, cash position and non-GAAP measures. Other 8-K filings describe matters such as the submission of proposals to stockholders at the annual meeting, voting outcomes for director elections, advisory votes on executive compensation and ratification of the independent registered public accounting firm.
Schrödinger has also used Form 8-K to disclose executive compensation and separation arrangements under Item 5.02, including a separation and release of claims agreement with a former executive vice president and chief financial officer. These filings outline severance-related payments, equity vesting terms, COBRA-related benefits and other contractual provisions, providing insight into the company’s executive compensation framework.
On Stock Titan, users can review SDGR’s 10-K and 10-Q filings for detailed discussions of its software and drug discovery activities, risk factors, segment information and accounting policies. AI-powered summaries help explain lengthy filings by highlighting important sections, such as revenue breakdowns between software and drug discovery, non-GAAP reconciliations and disclosures related to collaborations and equity investments. The platform also surfaces Form 4 insider transaction reports, allowing users to track equity awards and share transactions by directors and officers.
With real-time updates from EDGAR and AI-generated overviews, the Schrödinger SEC filings page is intended to make it easier to navigate complex regulatory documents, compare periods and understand how SDGR’s computational platform, collaborations and therapeutics portfolio are reflected in its official disclosures.
Schrodinger, Inc. received an updated ownership report from Rubric Capital Management and David Rosen. They report beneficial ownership of 4,171,498 shares of Schrodinger common stock, representing 6.47% of the company’s outstanding shares.
The shares are held through Rubric-managed funds, including Rubric Capital Master Fund LP, with Rubric and Rosen sharing voting and dispositive power over the reported stake. The percentage ownership is calculated using 64,500,510 Schrodinger shares outstanding as of October 29, 2025, as disclosed in the company’s recent quarterly report. The filers certify that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Schrodinger.
Schrodinger, Inc. executive Yvonne Tran, EVP, CLO & CPO, sold 776 shares of common stock on 02/10/2026 at a weighted average price of $13.7956. The sale was executed under a durable Rule 10b5-1 automatic instruction to cover withholding taxes from vesting restricted stock units and was not a discretionary trade. Following this transaction, Tran beneficially owned 22,859 shares, including 14,398 unvested RSUs.
Schrodinger, Inc. executive Kenneth Patrick Lorton reported a small automatic sale of common stock tied to tax withholding. On 02/10/2026, he sold 925 shares of Schrodinger common stock in an open-market transaction at a weighted average price of $13.7338 per share under a pre-established Rule 10b5-1 plan. The sale was executed by a broker to cover withholding taxes arising from the vesting of restricted stock units and is described as non-discretionary. After this transaction, Lorton directly beneficially owned 52,651 shares of common stock, including 14,543 unvested RSUs.
Schrodinger, Inc.’s Chief Accounting Officer Jenny Herman reported an open-market sale of common stock. On February 10, 2026, she sold 752 shares at a weighted average price of $13.7904 under a pre-established Rule 10b5-1 trading plan to cover withholding taxes from RSU vesting.
After this transaction, she directly beneficially owns 26,597 shares of Schrodinger common stock, which includes 17,285 unvested RSUs. The filing notes the sale was not a discretionary trade and that the shares were sold in multiple transactions between $13.71 and $13.85.
Abel Robert Lorne reported open-market sale transactions in a Form 4 filing for SDGR. The filing lists transactions totaling 1,230 shares at a weighted average price of $13.51 per share. Following the reported transactions, holdings were 19,385 shares.
A shareholder in the issuer plans to sell 752 shares of common stock, with an aggregate market value of $10,370.38, through Fidelity Brokerage Services LLC on or around 02/10/2026 on NASDAQ. These shares were acquired on 02/09/2026 via restricted stock vesting from the issuer as compensation. The filing notes there are 64,500,510 shares of this class outstanding and confirms the seller’s representation that they are not aware of undisclosed material adverse information about the issuer.
Schrödinger, Inc. insider plans to sell 925 common shares under Rule 144. The shares are to be sold through Fidelity Brokerage Services LLC on or about 02/10/2026 on NASDAQ, with an aggregate market value listed as 12703.77.
The 925 shares were acquired on 02/09/2026 through restricted stock vesting from the issuer as compensation. The notice states that the person signing does not know any undisclosed material adverse information about the issuer’s operations. The table also notes 64500510 shares or units outstanding.
Schrödinger Inc. (SDGR) filed a Form 144 notice for a planned small stock sale. The filing covers 776 shares of common stock to be sold through Fidelity Brokerage Services LLC on or about 02/10/2026 on NASDAQ, with an aggregate market value of $10,705.39.
The shares were acquired on 02/09/2026 via restricted stock vesting from the issuer as compensation. The form states that the person for whose account the securities are to be sold represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
A holder of SDGR common stock filed a Rule 144 notice to sell 1,230 shares through Merrill Lynch Wealth Management on the NASDAQ, with an aggregate market value of 16518.9. The issuer reported 64,500,510 shares outstanding.
The securities to be sold were originally acquired as a stock bonus from the issuer on 02/09/2023, when the holder received 2,636 common shares as consideration. The planned sale date is approximately 02/09/2026, and the filer represents they are not aware of undisclosed material adverse information about the issuer.
Schrödinger, Inc. (SDGR) reported Q3 2025 results with total revenue of $54,324, up from $35,290 a year ago, and a narrower net loss of $32,795 versus $38,136. For the first nine months, revenue reached $168,634 compared with $119,222, while net loss improved to $135,776 from $146,907.
Software products and services delivered $40,858 in Q3, led by on-premise software $15,928, hosted software $11,585, maintenance $6,826, professional services $1,589, and software contributions $4,930. Drug discovery revenue was $13,466, including $13,008 from services and $458 from contributions.
Operating expenses declined year over year, with research and development $42,757, sales and marketing $9,524, and general and administrative $21,705. Cash and cash equivalents were $172,120 and marketable securities $219,113 at quarter end. Deferred revenue totaled $82,283 short‑term and $92,390 long‑term; the company expects to recognize approximately 47% of its September 30, 2025 deferred revenue in the next 12 months.
Collaboration revenue included $8.8 million from Novartis in Q3 and $0.7 million from the BMS agreement. As of October 29, 2025, there were 64,500,510 common shares and 9,164,193 limited common shares outstanding.